High-throughput rational design of the remdesivir binding site in the RdRp of SARS-CoV-2: implications for potential resistance

The use of remdesivir to treat COVID-19 will likely continue before clinical trials are completed. Due to the lengthening pandemic and evolving nature of the virus, predicting potential residues prone to mutation is crucial for the management of remdesivir resistance. Using a rational ligand-based i...

Descripción completa

Detalles Bibliográficos
Autores principales: Padhi, Aditya K., Shukla, Rohit, Saudagar, Prakash, Tripathi, Timir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7807151/
https://www.ncbi.nlm.nih.gov/pubmed/33490902
http://dx.doi.org/10.1016/j.isci.2020.101992

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7807151/
https://www.ncbi.nlm.nih.gov/pubmed/33490902
http://dx.doi.org/10.1016/j.isci.2020.101992

Ejemplares similares